Cytek Biosciences (CTKB) Short Interest Ratio & Short Volume $4.15 +0.14 (+3.49%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.14 -0.01 (-0.12%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cytek Biosciences Short Interest DataCytek Biosciences (CTKB) has a short interest of 5.10 million shares, representing 4.43% of the float (the number of shares available for trading by the public). This marks a -9.73% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.9, indicating that it would take 3.9 days of the average trading volume of 1.17 million shares to cover all short positions.Current Short Interest5,100,000 sharesPrevious Short Interest5,650,000 sharesChange Vs. Previous Month-9.73%Dollar Volume Sold Short$18.36 millionShort Interest Ratio3.9 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares127,220,000 sharesFloat Size115,120,000 sharesShort Percent of Float4.43%Today's Trading Volume782,501 sharesAverage Trading Volume1,172,731 sharesToday's Volume Vs. Average67% Short Selling Cytek Biosciences? Sign up to receive the latest short interest report for Cytek Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCTKB Short Interest Over TimeCTKB Days to Cover Over TimeCTKB Percentage of Float Shorted Over Time Cytek Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/20255,100,000 shares $18.36 million -9.7%4.4%3.9 $3.60 7/15/20255,650,000 shares $18.36 million +19.2%4.9%5 $3.25 6/30/20254,740,000 shares $16.12 million -6.9%4.1%4.1 $3.40 6/15/20255,090,000 shares $16.39 million -5.9%4.4%4.6 $3.22 5/31/20255,410,000 shares $15.04 million +16.3%4.7%5.2 $2.78 5/15/20254,650,000 shares $12.46 million +11.0%4.1%5.2 $2.68 4/30/20254,190,000 shares $15.54 million +1.2%3.7%5.1 $3.71 4/15/20254,140,000 shares $15.40 million -8.6%3.6%5 $3.72 3/31/20254,530,000 shares $18.17 million +18.9%3.9%5.2 $4.01 3/15/20253,810,000 shares $16.00 million +10.4%3.3%4.6 $4.20 Get the Latest News and Ratings for CTKB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. 2/28/20253,450,000 shares $15.49 million -0.3%3.0%4.7 $4.49 2/15/20253,460,000 shares $18.10 million +9.2%3.0%5 $5.23 1/31/20253,170,000 shares $16.33 million -8.7%2.7%4 $5.15 1/15/20253,470,000 shares $19.71 million -0.3%3.0%4.7 $5.68 12/31/20243,480,000 shares $22.59 million -5.7%3.0%5.3 $6.49 12/15/20243,690,000 shares $22.91 million -6.6%3.2%5.6 $6.21 11/30/20243,950,000 shares $25.79 million -3.9%3.4%5.6 $6.53 11/15/20244,110,000 shares $24.45 million -2.1%3.5%6 $5.95 10/31/20244,200,000 shares $20.79 million -6.0%3.6%6.2 $4.95 10/15/20244,470,000 shares $23.87 million +4.0%3.7%7.4 $5.34 9/30/20244,300,000 shares $23.82 million +5.4%3.6%6.8 $5.54 9/15/20244,080,000 shares $20.03 million -11.5%3.4%5.7 $4.91 8/31/20244,610,000 shares $26.46 million +0.7%3.9%6.8 $5.74 8/15/20244,580,000 shares $24.78 million -16.3%3.8%7 $5.41 7/31/20245,470,000 shares $36.70 million -13.7%4.6%8 $6.71 7/15/20246,340,000 shares $40.13 million -1.7%5.3%9.6 $6.33 6/30/20246,450,000 shares $35.99 million -0.2%5.4%9.4 $5.58 6/15/20246,460,000 shares $36.31 million -0.2%5.4%9.9 $5.62 5/31/20246,470,000 shares $36.43 million -1.7%5.4%9.3 $5.63 5/15/20246,580,000 shares $40.14 million -16.2%5.5%9 $6.10 4/30/20247,850,000 shares $47.18 million +5.1%6.6%11.2 $6.01 4/15/20247,470,000 shares $44.97 million -24.9%6.3%10.8 $6.02 3/31/20249,950,000 shares $66.76 million +16.9%8.4%13.8 $6.71 3/15/20248,510,000 shares $59.14 million +9.2%7.1%11.6 $6.95 2/29/20247,790,000 shares $59.98 million +4.6%6.3%10.2 $7.70 2/15/20247,450,000 shares $64.96 million -2.5%6.3%9.1 $8.72 1/31/20247,640,000 shares $57.68 million No Change6.6%8.1 $7.55 1/15/20247,640,000 shares $62.72 million +5.2%6.6%7.1 $8.21 12/31/20237,260,000 shares $66.21 million -5.2%6.3%6.5 $9.12 12/15/20237,660,000 shares $69.55 million -3.8%6.6%7.1 $9.08Nations are at war over what’s in this box (Ad)A resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldman Sachs calls it “The New Oil.” The International Energy Agency says it’s a cornerstone for electricity-related technologies. And the U.S. Department of Energy has officially classified it as “Critical.” Global demand is surging, supply is tightening fast, and one company may be positioned for a potential 3,500% windfall as the world races to secure it.Click here to see the full Element 29 story and the company behind it. 11/30/20237,960,000 shares $55.24 million -5.0%6.9%7.2 $6.94 11/15/20238,380,000 shares $47.85 million +5.8%7.2%7.8 $5.71 10/31/20237,920,000 shares $33.34 million +0.6%6.8%8.1 $4.21 10/15/20237,870,000 shares $39.51 million -2.8%6.7%8.9 $5.02 9/30/20238,100,000 shares $44.71 million -31.8%6.9%9.5 $5.52 9/15/202311,880,000 shares $83.16 million +0.5%10.4%14.2 $7.00 8/31/202311,820,000 shares $89.83 million +2.7%10.3%14.8 $7.60 8/15/202311,510,000 shares $100.25 million -4.2%10.1%15.2 $8.71 7/31/202312,020,000 shares $107.70 million +4.9%11.0%12.3 $8.96 7/15/202311,460,000 shares $103.25 million +9.4%10.5%8.3 $9.01 6/30/202310,480,000 shares $89.50 million +11.4%9.6%7.6 $8.54 6/15/20239,410,000 shares $81.68 million +8.4%8.6%6.8 $8.68 5/31/20238,680,000 shares $67.79 million -22.6%8.0%6.5 $7.81 5/15/202311,210,000 shares $81.61 million +66.1%10.3%8.3 $7.28 4/30/20236,750,000 shares $77.49 million +3.7%7.2%6.2 $11.48 4/15/20236,510,000 shares $66.27 million +15.2%6.0%9.6 $10.18 3/31/20235,650,000 shares $51.92 million -2.4%5.2%8.2 $9.19 3/15/20235,790,000 shares $56.16 million +1.1%5.3%8.3 $9.70 2/28/20235,730,000 shares $59.02 million +4.4%5.3%8.8 $10.30 2/15/20235,490,000 shares $65.50 million +7.7%5.2%8.8 $11.93 1/31/20235,100,000 shares $61.46 million +28.5%5.6%8.3 $12.05 1/15/20233,970,000 shares $43.63 million +9.7%4.3%6.6 $10.99 12/30/20223,620,000 shares $36.96 million +4.3%4.3%6.5 $10.21 12/15/20223,470,000 shares $37.44 million +20.9%4.1%5.9 $10.79 11/30/20222,870,000 shares $36.99 million +3.6%3.4%4.4 $12.89 11/15/20222,770,000 shares $40.86 million -14.8%3.3%4.1 $14.75 10/31/20223,250,000 shares $50.44 million -13.8%4.4%4.8 $15.52 10/15/20223,770,000 shares $54.25 million -9.4%5.0%5.6 $14.39 9/30/20224,160,000 shares $61.24 million +51.3%5.6%6.2 $14.72 9/15/20222,750,000 shares $38.20 million +3.8%3.7%4 $13.89 8/31/20222,650,000 shares $30.87 million -4.0%3.6%4.3 $11.65 8/15/20222,760,000 shares $41.32 million -12.1%3.7%4 $14.97 7/31/20223,140,000 shares $40.19 million -2.2%4.2%4.2 $12.80 7/15/20223,210,000 shares $38.62 million -10.1%4.0%4.2 $12.03 6/30/20223,570,000 shares $38.31 million -9.6%4.5%4.7 $10.73 6/15/20223,950,000 shares $38.99 million -4.8%4.9%5 $9.87 5/31/20224,150,000 shares $40.30 million -7.8%5.2%3.8 $9.71 5/15/20224,500,000 shares $42.21 million +22.0%5.6%3.8 $9.38 4/30/20223,690,000 shares $34.87 million -4.9%4.9%3 $9.45 4/15/20223,880,000 shares $40.24 million -6.7%5.1%3.2 $10.37 3/31/20224,160,000 shares $44.84 million +321.4%5.5%3.6 $10.78 3/15/2022987,100 shares $12.03 million +9.5%1.3%0.9 $12.19 2/28/2022901,700 shares $12.30 million +44.7%1.2%1.3 $13.64 2/15/2022623,300 shares $9.35 million -30.0%0.8%1.2 $15.00 1/31/2022890,500 shares $12.97 million -12.7%1.2%2.9 $14.56 1/15/20221,020,000 shares $14.01 million +7.4%1.4%5.1 $13.74 12/31/2021949,900 shares $15.50 million +42.0%1.3%5.2 $16.32 12/15/2021669,000 shares $12.27 million +15.7%0.9%3.4 $18.34 11/30/2021578,100 shares $11.66 million -16.8%0.8%2.4 $20.17 11/15/2021695,100 shares $16.10 million -7.3%0.9%2.7 $23.16Nations are at war over what’s in this box (Ad)A resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldman Sachs calls it “The New Oil.” The International Energy Agency says it’s a cornerstone for electricity-related technologies. And the U.S. Department of Energy has officially classified it as “Critical.” Global demand is surging, supply is tightening fast, and one company may be positioned for a potential 3,500% windfall as the world races to secure it.Click here to see the full Element 29 story and the company behind it. 10/29/2021749,600 shares $17.10 million -3.2%0.9%2.9 $22.81 10/15/2021774,200 shares $18.63 million +31.6%1.0%2.6 $24.07 9/30/2021588,500 shares $12.60 million +206.2%0.7%1.5 $21.41 9/15/2021192,200 shares $5.37 million +330.0%0.2%0.5 $27.93 8/31/202144,700 shares $1.02 million -51.2%0.2%0.1 $22.78 8/13/202191,600 shares $1.89 million No Change0.1%0.2 $20.67 CTKB Short Interest - Frequently Asked Questions What is Cytek Biosciences' current short interest? Short interest is the volume of Cytek Biosciences shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 5,100,000 shares of CTKB short. 4.43% of Cytek Biosciences' shares are currently sold short. Learn More on Cytek Biosciences' current short interest. What is a good short interest ratio for Cytek Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CTKB shares currently have a short interest ratio of 4.0. Learn More on Cytek Biosciences's short interest ratio. What is a good short interest percentage for Cytek Biosciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.43% of Cytek Biosciences' floating shares are currently sold short. Is Cytek Biosciences' short interest increasing or decreasing? Cytek Biosciences saw a decrease in short interest in July. As of July 31st, there was short interest totaling 5,100,000 shares, a decrease of 9.7% from the previous total of 5,650,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cytek Biosciences' float size? Cytek Biosciences currently has issued a total of 127,224,000 shares. Some of Cytek Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cytek Biosciences currently has a public float of 115,120,000 shares. How does Cytek Biosciences' short interest compare to its competitors? 4.43% of Cytek Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "measuring and control equipment" compare to Cytek Biosciences: 10x Genomics (12.96%), Eyepoint Pharmaceuticals, Inc. (10.49%), Transcat, Inc. (4.40%), Allient Inc. (2.82%), Aehr Test Systems (20.74%), Standard BioTools Inc. (3.31%), Senseonics Holdings, Inc. (8.14%), Frequency Electronics, Inc. (9.44%), 908 Devices Inc. (7.68%), Quantum-Si Incorporated (14.36%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Cytek Biosciences stock? Short selling CTKB is an investing strategy that aims to generate trading profit from Cytek Biosciences as its price is falling. CTKB shares are trading up $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cytek Biosciences? A short squeeze for Cytek Biosciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CTKB, which in turn drives the price of the stock up even further. How often is Cytek Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CTKB, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies 10x Genomics Short Interest Eyepoint Pharmaceuticals Short Interest Transcat Short Interest Allient Short Interest Aehr Test Systems Short Interest Standard BioTools Short Interest Senseonics Short Interest Frequency Electronics Short Interest 908 Devices Short Interest Quantum-Si Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CTKB) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access